Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll A work in progress: the clinical development of histone deacetylase inhibitors Marsoni S; Damia G; Camboni GEpigenetics 2008[May]; 3 (3): 164-71It has been widely recognized that histone deacetylases (HDAC) are promising targets in the field of oncology. An impressive body of preclinical research points to the ability of HDAC inhibitors (HDACIs) to modulate a wide variety of cellular functions, including cell differentiation, cell cycle progression, apoptosis, cytoskeletal modifications and angiogenesis. Originally developed as epigenetic drugs because of their ability to inhibit histones deacetylation, HDACIs are now being considered also because of their effects on other acetylation-regulated proteins with pivotal roles in transformed cells. This review will highlight the clinical development of HDACIs in oncology and will try to discuss the several major open clinical issues challenging the successful clinical development of HDACIs, with a particular emphasis on the spectrum of activity of these agents, the best development strategy in solid tumors, the cardiac side effects and bio-markers to be used in clinical trials.|*Histone Deacetylase Inhibitors[MESH]|Antineoplastic Agents/chemistry/*therapeutic use[MESH]|Benzamides[MESH]|Clinical Trials as Topic[MESH]|Enzyme Inhibitors/chemistry/*therapeutic use[MESH]|Humans[MESH]|Hydroxamic Acids[MESH]|Neoplasms/*drug therapy/enzymology[MESH] |